An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractory CD19+ diffuse large B cell lymphoma

Trial Profile

An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractory CD19+ diffuse large B cell lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs Coltuximab ravtansine (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms STARLYTE
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Jan 2017 This trial was completed in Italy (end date: 2016-10-04), according to European Clinical Trials Database.
    • 04 Nov 2016 This trial was completed in Belgium, according to European Clinical Trials Database.
    • 20 Oct 2016 This trial was completed in Spain (end date: 2016-10-04), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top